Lately, Shanghai FTZ Fund has invested in Koka Life Sciences,  an innovative company dedicated to the research and development of domestic structural heart disease treatment products.

Koka Life Sciences was established in 2018 and has decades of experience in the R&D of cardiovascular medical field. The company's technological level is at the absolute forefront in China and is synchronized with the most advanced cardiac medical treatment technologies worldwide. In 2021, the company was selected as one of the Top 100 Innovative Medical Device Companies in China by the Zhong Nanshan Medical Foundation, and was also selected as a potential unicorn company in China by GEI in 2020.